Most Read Articles
one year ago
Topical pine tar is safe and effective for the treatment of common skin conditions, based on a review.
2 years ago
Disease severity is associated with the presence of Malassezia species on skin of patients with seborrheic dermatitis based on a study.
2 years ago
Hair loss is a common problem for both men and women. Despite the various treatments available, hair loss remains a difficult condition to treat in most people. To gain better insights into the science behind hair loss, an interview was conducted recently with Dr Jia-Wei Liu, member of the European Hair Research Society and Vice President of Research and Development at Legacy Healthcare, Switzerland. The interview focused on hair loss and its management with CG 210TM, a novel botanical hair and scalp essence. 
Dr. Joseph Delano Fule Robles, 5 months ago

Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer. 

Reporting of harm severity in dermatology trials needs improvement

18 days ago

Studies in dermatology journals report harm quite well, according to a systematic review, adding that efforts should be made on reporting harm severity.

Researchers conducted a methodologic systematic review of dermatologic randomized controlled trials (RCTs) published from 2010 to 2014 in five dermatology journals to describe harm reporting and assess parameters that could influence the quality of harm reporting.

A total of 110 publications on RCTs were included. Of these, 80 (73 percent) adequately reported harm and 52 percent adequately reported its severity.

The type of trial (odds ratio [OR], 4.41; 95 percent CI, 1.60 to 12.35 for multicentre vs monocentric trials) and having a predefined method for collecting harm data (OR, 5.93; 2.26 to 15.56) were significantly associated with the adequate reporting of harm.

Reporting of harm severity was better in pharmacologic trials (OR, 6.48; 2.00 to 21.0) vs nonpharmacologic trials and in trials for which a method for collecting harm (OR, 5.65; 2.00 to 16.4) and its severity (OR, 3.60; 1.00 to 12.8) was defined prior to the commencement of the study.

This systematic review was limited by the assessment of RCTs and five dermatology journals only.

RCTs are regarded as the “gold standard” for evaluating efficacy and short-term harm of medicines, according to researchers.

In a previous study that evaluated RCTs (n=98) published in two dermatology journals pre- and post-CONSORT (Consolidated Standards for Reporting Trials) adoption, researchers found that the reporting quality of such RCTs needs improvement. Pharmaceutical industry funding was one of the factors associated with a good methodological quality. [Br J Dermatol 2009;161:1159-65]

Editor's Recommendations
Most Read Articles
one year ago
Topical pine tar is safe and effective for the treatment of common skin conditions, based on a review.
2 years ago
Disease severity is associated with the presence of Malassezia species on skin of patients with seborrheic dermatitis based on a study.
2 years ago
Hair loss is a common problem for both men and women. Despite the various treatments available, hair loss remains a difficult condition to treat in most people. To gain better insights into the science behind hair loss, an interview was conducted recently with Dr Jia-Wei Liu, member of the European Hair Research Society and Vice President of Research and Development at Legacy Healthcare, Switzerland. The interview focused on hair loss and its management with CG 210TM, a novel botanical hair and scalp essence. 
Dr. Joseph Delano Fule Robles, 5 months ago

Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer.